GENE ONLINE|News &
The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq
AbbVie has published its financial report recently, showing that its top-selling drug Humira, known as adalimumab, has made great sales again at USD 20.7 billion. Humira has been the best-selling monoclonal antibody drug of AbbVie since marketing, however, is going to lose the protection from patent regulation in 2023. Pharmaceutical companies with biosimilar molecule drugs are expected to join the fierce competition, including Amgen, Samsung, Boehringer Ingelheim, Mylan, Novartis, and Pfizer.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
